FDA clears Bard's biliary stent:
This article was originally published in Clinica
CR Bard has received US FDA 510(k) clearance for its next-generation self-expanding nitinol biliary stent for treating malignant biliary obstructions. The product uses the company's radiopaque marker technology that improves radiopacity, allowing for better stent visualisation before and after the stent has been placed. Nitinol stents are rapidly becoming the product of choice for treating malignant biliary obstructions, which affect over 30,000 people in the US every year, says the Murray Hill, New Jersey company. The stent is being marketed through Bard's Peripheral Technologies division.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.